You are here

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
The Savin Center
New Haven, Connecticut, 06511 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Clinical diagnosis of stable mild-to-moderate plaque-type psoriasis involving 2-35% of
total body surface area (BSA) excluding face, scalp, and genitals

- Willingness and ability to apply study medication as directed, comply with study
instructions, and commit to attending all study visits

- Women of childbearing potential must agree to use contraception for the entire study
period

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any dermatological conditions that could interfere with clinical evaluations

- Concurrent or recent use of certain topical or systemic medications without a
sufficient washout period

- Significant confounding conditions as assessed by study doctor

- Participated in any other trial of an investigational drug within 30 days or
participation in a research study concurrent with this study

- Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)

- Use of a beta-blocking medication (e.g., propranolol) if the dose has not been
stabilized for at least 3 months

- Pregnancy or lactation

NCT01300052
Pfizer
Completed
AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis
A Multicenter, Randomized, Double-Blind, 12-Week Study Of The Safety And Efficacy Of AN2728 Versus AN2728 Vehicle In The Treatment Of Patients With Mild-To-Moderate Plaque-Type Psoriasis
The purpose of this study is to determine whether AN2728 topical ointment is a safe and effective treatment for mild-to-moderate plaque-type psoriasis.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Psoriasis
  • Drug: AN2728 ointment, 2%
    AN2728 ointment, 2%, applied twice daily for 12 weeks
  • Drug: Ointment Vehicle
    Ointment Vehicle, applied twice daily for 12 weeks
  • Experimental: AN2728 ointment, 2%
    AN2728 ointment, 2%
    Intervention: Drug: AN2728 ointment, 2%
  • Placebo Comparator: Ointment Vehicle
    Ointment Vehicle
    Intervention: Drug: Ointment Vehicle
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
68
June 6, 2011
June 6, 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of stable mild-to-moderate plaque-type psoriasis involving 2-35% of total body surface area (BSA) excluding face, scalp, and genitals
  • Willingness and ability to apply study medication as directed, comply with study instructions, and commit to attending all study visits
  • Women of childbearing potential must agree to use contraception for the entire study period

Exclusion Criteria:

  • Any dermatological conditions that could interfere with clinical evaluations
  • Concurrent or recent use of certain topical or systemic medications without a sufficient washout period
  • Significant confounding conditions as assessed by study doctor
  • Participated in any other trial of an investigational drug within 30 days or participation in a research study concurrent with this study
  • Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)
  • Use of a beta-blocking medication (e.g., propranolol) if the dose has not been stabilized for at least 3 months
  • Pregnancy or lactation
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01300052
AN2728-PSR-204
C3291017 ( Other Identifier: Alias Study Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer Pfizer CT.gov Call Center Pfizer
Pfizer
March 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now